The development of PSA guidelines in Australia. Presented by Dr Peter Heathcote

THIS TALK WAS PRESENTED LIVE DURING THE INAUGURAL MEDD LIVE 2020 VIRTUAL MEDICAL CONFERENCE

The development of PSA guidelines in Australia

Learning Objectives:
1. Who and how to offer PSA testing to men
2. Understanding the risk stratification of newly diagnosed prostate cancer
3. Understanding management options in early prostate cancer, in particular, the increasing use of Active Surveillance and improvements in the morbidity of radical prostatectomy and radiation therapy

Abstract:
The role of Prostate-Specific Antigen (PSA) in the early detection of prostate cancer has caused controversy since it's introduction in the 1990s. In 2016 Guidelines on the use of PSA in clinical practice were released and endorsed by the National Health and Medical Research Council (NHMRC). This presentation describes the development of the guidelines and also discusses the impact of multiparametric MRI and modern Active Surveillance protocols on risk stratification and harm minimization in men with PSA detected early prostate cancer.